Prevalence, severity, and treatment of Community-Acquired Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) skin and soft tissue infections in 10 medical clinics in Texas: A South Texas Ambulatory Research Network (STARNet) study

Journal of the American Board of Family Medicine

Volumn 24, Issue 5, 2011, Pages 543-550

  Forcade, Nicolas A ^a,b   Parchman, Michael L ^b,c   Jorgensen, James H ^b   Du, Liem C ^d   Nyren, Natalie R ^d   Treviño, Lucina B ^d   Peña, Joel ^d   Mann, Michael W ^d   Muñoz, Abilio ^d   Treviño, Sylvia B ^d   Mortensen, Eric M ^b,c   Wickes, Brian L ^b   Pollock, Brad H ^b   Frei, Christopher R ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^d South Texas Ambulatory Research Network (STARNet)   (United States)

Author keywords

Antibiotics; CA MRSA; Epidemiology; Practice based research; Soft tissue infections

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; LINEZOLID; PSEUDOMONIC ACID; VANCOMYCIN;

ABSCESS DRAINAGE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; ERYTHEMA; FEMALE; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PREVALENCE; PRIMARY MEDICAL CARE; SOFT TISSUE INFECTION; STAPHYLOCOCCAL SKIN INFECTION; UNITED STATES;

ADULT; ANTI-BACTERIAL AGENTS; CLINDAMYCIN; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; TEXAS;

EID: 80052874568     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2011.05.110073     Document Type: Article

References (30)

1. Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med 2008;168:1585-91.
2. Pallin DJ, Egan DJ, Pelletier AJ, et al. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med 2008;51:291-8.
3. Taira BR, Singer AJ, Thode HC Jr, Lee CC. National epidemiology of cutaneous abscesses: 1996 to 2005. Am J Emerg Med 2009;27:289-92.
4. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S aureus infections among patients in the emergency department. N Engl J Med 2006;355:666-74.
5. Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillinresistant Staphylococcus aureus. Pediatr Infect Dis J 2004;23:123-7. (Pubitemid 38222783)
6. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005;352:1436-44.
7. Paydar KZ, Hansen SL, Charlebois ED, et al. Inappropriate antibiotic use in soft tissue infections. Arch Surg 2006;141:850-4. (Pubitemid 44414426)
8. Ruhe JJ, Smith N, Bradsher RW, Menon A. Community- onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 2007;44:777-84. (Pubitemid 46365300)
9. Duong M, Markwell S, Peter J, Barenkamp S. Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. Ann Emerg Med 2010;55:401-7.
10. Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007;51:4044-8. (Pubitemid 350057804)
11. Schmitz GR, Bruner D, Pitotti R, et al. Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection. Ann Emerg Med 2010;56:283-7.
12. Ruhe JJ, Menon A. Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007;51:3298-303. (Pubitemid 350067543)
13. Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007;51:423-8. (Pubitemid 46185256)
14. Frazee BW, Lynn J, Charlebois ED, et al. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med 2005;45:311-20. (Pubitemid 40261163)
15. King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006;144:309-17. (Pubitemid 46768185)
16. Frei CR, Miller ML, Lewis JS 2nd, et al. Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections. J Am Board Fam Med 2010;23:714-9.
17. Parchman ML, Munoz A. Risk factors for methicillin-resistant Staphylococcal aureus skin and soft tissue infections presenting in primary care: a South Texas Ambulatory Research Network (STARNet) study. J Am Board Fam Med 2009;22:375-9.
18. Khawcharoenporn T, Tice A. Empiric outpatient therapy with trimethoprim-sulfamethoxazole, cephalexin, or clindamycin for cellulitis. Am J Med 2010;123:942-50.
19. CLSI. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100- S17. Wayne, PA: Clinical and Laboratory Standards Institute; 2007.
20. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: uncomplicated and complicated skin and skin structure infections: developing antimicrobial drugs for treatment. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071185.pdf. Accessed January 20, 2011.
21. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Draft guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment. August 2010. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071185.pdf. Accessed January 21, 2011.
22. Eron LJ, Lipsky BA, Low DE, et al Expert Panel on Managing Skin and Soft Tissue Infections. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003;52(Suppl S1):i3-17.
23. Ki V, Rotstein C. Bacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can J Infect Dis Med Microbiol 2008;19:173-84. (Pubitemid 351754184)
24. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-406. (Pubitemid 41581713)
25. Gorwitz RJ, Jernigan DB, Powers JH, and Participants in the CDC Convened Experts' Meeting on Management of MRSA in the Community. Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006. Available at http://www.cdc.gov/ncidod/dhqp/ar-mrsa- ca.html. Accessed January 10, 2011.
26. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:18-55.
27. LoVecchio F, Perera N, Casanova L, et al. Boardcertified emergency physicians' treatment of skin and soft tissue infections in the community-acquired methicillin-resistant Staphylococcus aureus era. Am J Emerg Med 2009;27:68-70.
28. Lewis JS 2nd, Jorgensen JH. Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis 2005;40:280-5. (Pubitemid 40110675)
29. Draghi DC, Sheehan DF, Hogan P, Sahm DF. Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting. Diagn Microbiol Infect Dis 2006;55:129-33. (Pubitemid 43775918)
30. Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillinresistant Staphylococcus aureus. J Infect Dis 2007;195:202-11. (Pubitemid 46080052)